<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Prospective Grant of an Exclusive Patent License: The Development of Bispecific Antibodies Targeting Glypican 1 (GPC1) for the Treatment of GPC1-Expressing Human Cancer</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Prospective Grant of an Exclusive Patent License: The Development of Bispecific Antibodies Targeting Glypican 1 (GPC1) for the Treatment of GPC1-Expressing Human Cancer</h1>
    <p class="timestamp">Published: 2020-04-02 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to NeoImmune Tech, Inc. (NeoImmune), located in Rockville, Maryland.</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, National Institutes of Health</p>
    <p><strong>Document Number:</strong> 2020-06917</p>
    <p><strong>Publication Date:</strong> 2020-04-02</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2020/04/02/2020-06917/prospective-grant-of-an-exclusive-patent-license-the-development-of-bispecific-antibodies-targeting">https://www.federalregister.gov/documents/2020/04/02/2020-06917/prospective-grant-of-an-exclusive-patent-license-the-development-of-bispecific-antibodies-targeting</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2020-06917</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
